Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in ...

Q4 2024 Earnings Call Transcript March 10, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 ---- Advancing four clinical programs for ...

At the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium ... including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other ...

CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- -- $249.4 ...

The results are still preliminary, but Pfizer said that if it hits primary endpoints later this year could form ... its full dose once a week thereafter. J&J also reported new data at ASCO from ...

Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, ...

CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study; Fast Track Designation granted by ...

ASCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, order of components, figure ...

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures -- UDENYCA® net revenue increased 62% year-over-year -- LOQTORZI® net revenue increased 29% quarter-over-qua ...

Almee takes the form of a nine-week CBT course that has been ... The Swedish company says it plans to present full results from the COMPANION study at a conference later this year and is looking ...